Dr Neil Cashman examines the recent news around Biogen's Alzheimer's treatment aducanumab, assuages some investor fears, and underlines the…

Dr Neil Cashman looks at the potential impact of US FDA approval for Biogen's aducanumab on the search for Alzheimer's Disease (AD) treatments, and…

BioArctic is a Swedish biopharma company with the vision to become a world-leader in the research and development of disease-modifying treatments for…

Swedish biotech BioArctic, in collaboration with Japanese firm Eisai, has seen positive Phase IIb results for its BAN2401 antibody – potentially the…

Alzheimer's drugs represent a high-risk, high-reward proposition for global pharma. As David H. Crean recently wrote for PharmaBoardroom, "Except for…

David H. Crean highlights R&D efforts and ongoing investments in Alzheimer’s disease treatments as we enter the month of June, brain awareness…

Cerecin's Charles Stacey looks at the large unmet medical need in diseases of the central nervous system (CNS), the looming socioeconomic burden that…

Martin Dubuc, general manager of Biogen France, discusses the company’s strong leadership in neurosciences, its commitment to pioneering the…

Joël Jaouen, president of France Alzheimer, provides important insights into the role and objectives of the patient association. He explains why…

Dr Charles Stacey, president and CEO of Brain Health company Cerecin, formerly Accera, discusses the rebrand, new investment, the company’s…

One notable quirk of the British life sciences ecosystem is the importance of its not-for-profit sector. Indeed, in 2017, UK charities poured GBP 1.6…

After completing Phase II of clinical trials, Biogen and Eisai’s new candidate drug for Alzheimer’s Disease is showing strong potential in a field…